BR112016013594A8 - formas cristalinas de um composto dihidroxi ciclopentil alfa, ômega-dissubstituído, composição farmacêutica, métodos para o preparo e uso das mesmas - Google Patents
formas cristalinas de um composto dihidroxi ciclopentil alfa, ômega-dissubstituído, composição farmacêutica, métodos para o preparo e uso das mesmas Download PDFInfo
- Publication number
- BR112016013594A8 BR112016013594A8 BR112016013594A BR112016013594A BR112016013594A8 BR 112016013594 A8 BR112016013594 A8 BR 112016013594A8 BR 112016013594 A BR112016013594 A BR 112016013594A BR 112016013594 A BR112016013594 A BR 112016013594A BR 112016013594 A8 BR112016013594 A8 BR 112016013594A8
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- omega
- preparing
- disubstituted
- cyclopentyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/559—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/28—Halogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
aqui previstas várias formas sólidas de um composto dihidroxi ciclopentil alfa, ômega-dissubstituído definido e métodos para o preparo e uso das mesmas. em um aspecto, são proporcionadas formas cristalinas do referido composto ciclopentil, e métodos para o preparo e uso das mesmas. em outro aspecto, são proporcionadas formas substancialmente amorfas de um composto dihidroxi ciclopentil alfa, ômega-dissubstituído, e métodos para o preparo e uso das mesmas. em ainda outro aspecto, são proporcionadas composições contendo compostos de acordo com a presente invenção. em certos aspectos, tais composições são adequadas para a entrega de agentes ativos de acordo com a presente invenção a um sujeito em necessidade dos mesmos. num outro aspecto da invenção, são proporcionados métodos para o tratamento de uma variedade de indicações, incluindo o glaucoma, hipertensão ocular, e semelhantes. em ainda outro aspecto da presente invenção, proporcionam-se kits contendo os compostos de acordo com a presente invenção e/ou composições contendo os mesmos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361915575P | 2013-12-13 | 2013-12-13 | |
PCT/US2014/070156 WO2015089475A1 (en) | 2013-12-13 | 2014-12-12 | Solid forms of an alpha, omega di-substituted dihydroxy cyclopentyl compound and methods for the preparation and use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112016013594A2 BR112016013594A2 (pt) | 2017-08-08 |
BR112016013594A8 true BR112016013594A8 (pt) | 2020-05-19 |
Family
ID=52282957
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112016013594A BR112016013594A8 (pt) | 2013-12-13 | 2014-12-12 | formas cristalinas de um composto dihidroxi ciclopentil alfa, ômega-dissubstituído, composição farmacêutica, métodos para o preparo e uso das mesmas |
Country Status (16)
Country | Link |
---|---|
US (2) | US9353079B2 (pt) |
EP (1) | EP3080096A1 (pt) |
JP (2) | JP2016539994A (pt) |
KR (1) | KR20160097310A (pt) |
CN (1) | CN105814033B (pt) |
AU (1) | AU2014361794B2 (pt) |
BR (1) | BR112016013594A8 (pt) |
CA (1) | CA2933556A1 (pt) |
CL (2) | CL2016001448A1 (pt) |
IL (2) | IL245917B (pt) |
MX (1) | MX2016007717A (pt) |
RU (1) | RU2730520C2 (pt) |
SA (1) | SA516371307B1 (pt) |
SG (2) | SG10201709702UA (pt) |
UA (1) | UA121108C2 (pt) |
WO (1) | WO2015089475A1 (pt) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
EP3658149B1 (en) * | 2017-07-25 | 2021-11-10 | Allergan, Inc. | Solid complex comprising (z)-7-((1r,2r,3r,5s)-2-((s,e)-5-(2,5-dichlorothiophen-3-yl)-3-hydroxypent-1-en-1-yl)-3,5-dihydroxycyclopentyl)hept-5-enamide, preparation and uses thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES416865A1 (es) * | 1972-07-13 | 1976-03-01 | Pfizer | Procedimiento para preparar w-pentanorprostaglandinas sus- tituidas en la posicion 15. |
US5296504A (en) * | 1988-09-06 | 1994-03-22 | Kabi Pharmacia | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
US5834498A (en) * | 1992-09-21 | 1998-11-10 | Allergan | Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
US6602900B2 (en) * | 1992-09-21 | 2003-08-05 | Allergan, Inc. | Cyclopentane heptan(ENE)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
US6124344A (en) * | 1993-12-28 | 2000-09-26 | Allergan Sales, Inc. | Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
CA2221110C (en) * | 1995-05-18 | 2009-08-04 | Allergan | Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents for the treatment of ocular hypertension |
-
2014
- 2014-12-12 KR KR1020167018489A patent/KR20160097310A/ko not_active Application Discontinuation
- 2014-12-12 AU AU2014361794A patent/AU2014361794B2/en not_active Ceased
- 2014-12-12 UA UAA201606260A patent/UA121108C2/uk unknown
- 2014-12-12 CN CN201480067663.3A patent/CN105814033B/zh not_active Expired - Fee Related
- 2014-12-12 CA CA2933556A patent/CA2933556A1/en not_active Abandoned
- 2014-12-12 BR BR112016013594A patent/BR112016013594A8/pt not_active IP Right Cessation
- 2014-12-12 SG SG10201709702UA patent/SG10201709702UA/en unknown
- 2014-12-12 JP JP2016538513A patent/JP2016539994A/ja active Pending
- 2014-12-12 WO PCT/US2014/070156 patent/WO2015089475A1/en active Application Filing
- 2014-12-12 US US14/569,210 patent/US9353079B2/en active Active
- 2014-12-12 RU RU2016123446A patent/RU2730520C2/ru active
- 2014-12-12 MX MX2016007717A patent/MX2016007717A/es unknown
- 2014-12-12 EP EP14824284.5A patent/EP3080096A1/en not_active Withdrawn
- 2014-12-12 SG SG11201604787SA patent/SG11201604787SA/en unknown
-
2016
- 2016-05-05 US US15/147,700 patent/US20170087163A1/en not_active Abandoned
- 2016-05-30 IL IL245917A patent/IL245917B/en active IP Right Grant
- 2016-06-10 CL CL2016001448A patent/CL2016001448A1/es unknown
- 2016-06-13 SA SA516371307A patent/SA516371307B1/ar unknown
-
2019
- 2019-02-22 CL CL2019000471A patent/CL2019000471A1/es unknown
- 2019-12-23 JP JP2019231685A patent/JP2020073513A/ja active Pending
-
2021
- 2021-06-08 IL IL283810A patent/IL283810A/en unknown
Also Published As
Publication number | Publication date |
---|---|
CL2019000471A1 (es) | 2019-07-12 |
UA121108C2 (uk) | 2020-04-10 |
RU2730520C2 (ru) | 2020-08-24 |
JP2020073513A (ja) | 2020-05-14 |
EP3080096A1 (en) | 2016-10-19 |
AU2014361794B2 (en) | 2019-04-04 |
CN105814033B (zh) | 2019-10-25 |
BR112016013594A2 (pt) | 2017-08-08 |
SG10201709702UA (en) | 2018-01-30 |
WO2015089475A1 (en) | 2015-06-18 |
US9353079B2 (en) | 2016-05-31 |
SG11201604787SA (en) | 2016-07-28 |
US20170087163A1 (en) | 2017-03-30 |
AU2014361794A1 (en) | 2016-06-16 |
CL2016001448A1 (es) | 2017-03-03 |
US20150166504A1 (en) | 2015-06-18 |
SA516371307B1 (ar) | 2018-10-04 |
IL245917B (en) | 2021-06-30 |
MX2016007717A (es) | 2016-09-09 |
KR20160097310A (ko) | 2016-08-17 |
IL283810A (en) | 2021-07-29 |
JP2016539994A (ja) | 2016-12-22 |
CA2933556A1 (en) | 2015-06-18 |
IL245917A0 (en) | 2016-08-02 |
CN105814033A (zh) | 2016-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SV2017005461A (es) | Benzamidas sustituidas con 1,3-tiazol-2-ilo | |
CL2015000942A1 (es) | Compuestos de benceno sustituido. | |
BR112017002053A2 (pt) | composto de acordo com a fórmula (i), composição farmacêutica, e usos de um composto | |
CL2015002635A1 (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
CL2016001895A1 (es) | Compuestos | |
BR112016028288A2 (pt) | ?composto, composição farmacêutica, métodos para tratamento de um indivíduo com uma doença ou condição e para inibir a quinase, e, uso de um composto? | |
CL2019002464A1 (es) | Formas cristalinas del derivado de 4-pirimidinsulfamida de aprocitentán. | |
BR112015015891A8 (pt) | Composição farmacêutica de solução sólida, e, uso de uma composição farmacêutica | |
CO7350655A2 (es) | Derivados de 5-fenoxi-3h-pirimidin-4-ona y su uso como inhibidores de la transcriptasa inversa del vih | |
UY36254A (es) | 2 – (morfolin-4-il) – 1,7-naftiridinas | |
UY37098A (es) | Moduladores de ror-gamma | |
EA201691590A1 (ru) | Бензимидазол-2-амины в качестве ингибиторов midhi | |
CL2013000018A1 (es) | Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros. | |
BR112016028818A2 (pt) | composição farmacêutica, métodos de tratamento de uma doença ou condição, de inibição da atividade de um polipeptídeo de fosfatidilinositol 3-quinase e de inibição de reações imunes excessivas ou destrutivas ou crescimento ou proliferação de células cancerosas, kit, composto, sal, isômero, ou uma mistura farmaceuticamente aceitável do mesmo, e, uso de um composto, um sal, isômero, ou uma mistura farmaceuticamente aceitável do mesmo. | |
CR20120591A (es) | Derivados de aminopirimidina como moduladores de la lrrk2 | |
BR112015029386A8 (pt) | uso de eribulina e lenvatinibe como terapia de combinação, composição farmacêutica compreendendo os mesmos e kit | |
BR112022010112A2 (pt) | Aminoquinolonas substituídas como inibidores de dgkalfa para ativação imunológica | |
DOP2016000253A (es) | Nuevos compuestos | |
CL2008001373A1 (es) | Compuestos derivados de fenilamino-benceno sustituidos; metodo de preparacion; composicion farmaceutica; kit farmceuticos; y uso de dichos compuestos en el tratamiento del cancer. | |
UY35293A (es) | Isotiazoles sustituidos con amino | |
BR112016028845A2 (pt) | composto, composição farmacêutica e uso de um composto | |
CL2015002606A1 (es) | Compuesto. | |
BR112017001334A2 (pt) | compostos de imidazopiridazina, seu uso e composição farmacêutica que os compreende | |
BR112017000246A2 (pt) | composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal | |
CL2012003322A1 (es) | Compuestos derivados de benzamida sustituidas; composicion farmacéutica; y uso en el tratamiento del cancer. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2700 DE 04-10-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |